Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.

Although there was a possible trend toward a higher rate of grade 3 or 4 hypertension in the matching-adjusted cabozantinib population compared with the regorafenib population, the confidence intervals for the estimate crossed zero (indicating no difference), and a test of the null hypothesis confirmed that the difference was not statistically significant ( p = 0.0611) (Fig. 4 and Supplemental Table S6).

also in 1,410 other papers